Pyrazolopyridine Compounds Targeting TLR7/8/9 for Autoimmune Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for autoimmune diseases like Systemic Lupus Erythematosus (SLE) are inadequate, with existing treatments being either ineffective or associated with significant toxicity and side effects, and there is a need for novel, steroid-free, and non-cytotoxic oral drugs that target Toll-Like Receptors (TLR7/8/9 to manage autoimmune and auto-inflammatory conditions effectively.
Innovation Solution
Development of novel organic compounds that act as antagonists of TLR7, TLR8, and TLR9, which inhibit these receptors' pathways, thereby reducing immune responses and providing therapeutic benefits for autoimmune diseases such as SLE and lupus nephritis without the adverse effects of traditional immunosuppressive drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional immunosuppressive drugs (e.g., corticosteroids) are used for long-term treatment of SLE, then anti-inflammatory effects are achieved, but toxicity and side effects increase significantly
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism (aberrant nucleic acid sensing through TLR7/8/9) rather than using broad-spectrum immunosuppression. By isolating and inhibiting only the defective TLR pathways responsible for autoimmune pathology while leaving other immune functions intact, the treatment achieves anti-inflammatory effects without the systemic toxicity of traditional corticosteroids
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that selectively bind to and inhibit TLR7/8/9 receptors. These compounds act as mediators between the aberrant nucleic acid sensing pathway and the downstream immune response, blocking the pathological signal transduction without requiring broad immunosuppression, thereby reducing toxicity while maintaining efficacy
2Reliability
If Belimumab is used for SLE treatment, then some therapeutic effect is achieved, but efficacy is modest and delayed, working in only a fraction of patients
Solution Approach 1:
The patent employs small molecule compounds that can orally penetrate and rapidly inhibit TLR7/8/9 pathways, providing quicker onset of action compared to monoclonal antibodies like Belimumab. The small molecules are designed for rapid absorption and distribution, enabling preliminary blockade of the aberrant immune activation before significant tissue damage occurs, thereby reducing the delayed efficacy problem
Solution Approach 2:
The patent changes the pharmacokinetic and pharmacodynamic parameters by using small molecule chemistry rather than large protein therapeutics. This enables oral administration, faster absorption, better tissue penetration, and more rapid onset of action. The small molecules can achieve therapeutic concentrations quickly and maintain sustained inhibition of TLR pathways, improving both speed and consistency of efficacy across patient populations
3Object-generated harmful factors
If TLR7/8/9 inhibition is implemented, then autoimmune response is reduced, but potential impact on infection defense must be managed
Solution Approach 1:
The patent applies local quality by selectively targeting only the endosomal TLR7/8/9 pathways that are aberrantly activated in autoimmune disease, while leaving other nucleic acid sensing pathways (such as cytosolic cGAS/STING) and other TLRs intact. This localized inhibition preserves the body's ability to detect and respond to viral and bacterial infections through alternative pathways, maintaining infection defense capability while suppressing autoimmune pathology
Data Source
AI summary
The present invention relates to compounds of formula (I), wherein R1, R2, R3 and R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.